XTNT Stock Forecast & Price Target

Xtant Medical Holdings is a promising investment, with the potential to see modest growth rates in the near term followed by a 10% CAGR through FY28, driven by strong revenue guidance and a focus on design, development, and commercialization of spinal implant and orthobiologic products. With a solid product pipeline, a network of distributors, and a target market of orthopedic and neurological surgeons, the company has a strong foundation for future growth. Furthermore, the recent sale of certain assets has improved the company's capital position and reduced debt, making it more financially stable. While there are risks related to competition and market conditions, the attractive valuation and potential for future growth make Xtant Medical a compelling investment opportunity.

Xtant Medical Holdings is poised for continued top-line growth through acquisitions and new product launches in the orthobiologics space, as seen with the acquisition of HEMOBLAST Bellows and the launch of Strata and CollagenX. However, the company's financials may be negatively impacted in the short-term due to seasonality and divested assets, leading to a decline in spinal implant revenue and a decrease in operating margins. Overall, the company's focus on orthobiologics and potential for expanding distribution could help move the stock higher, but caution should be exercised due to short-term uncertainties.